Table 1. Characteristics of the studied patients (sLCL-1 to-14) with an iEBVL and one patient with a post-transplant lymphoproliferative disorder (PTLD-1).

Patient number	Age	Sex	Country of origin	Transplanted organ	Time from transplantation to iEBVL (in days)	EBV cop/ml WB	Immunosuppressive regimen	PTLD	status at last FU
sLCL-1	66	m	Germany	SCT	26	3150	CSA, MTX	-	alive
sLCL-2	66	m	Germany	SCT	26	3150	CSA, MTX	-	alive
sLCL-3	56	f	Germany	KT	7456	9870	CyA, ST	+a	alive
sLCL-4	66	f	Spain	KT	1821	18600	CSA, MMF, ST	-	alive
sLCL-5	64	m	Germany	SCT	29	1000	FK, MMF	-	dead (relapsed ALL)
sLCL-6	66	f	Germany	KT	3024	1730	ST	-	alive
sLCL-7	68	m	Germany	SCT	26	2390	CSA	-	alive
sLCL-8	46	f	Russia	SCT	41	2330	CSA	-	alive
sLCL-9	64	m	Germany	SCT	35	2600	CSA	-	alive
sLCL-10	60	f	Germany	KT	2853	1920	BELA/ST	-	alive
sLCL-11	63	m	Germany	SCT	273	16200	FK	-	alive
sLCL-12	56	f	Turkey	KT	18	8450	CSA, MMF, ST	-	alive
sLCL-13	32	m	Germany	KT	22	22600	CSA, ST	-	alive
sLCL-14	37	m	Germany	KT	810	16400	FK, MMF, ST	-	alive
PTLD-1	49	m	Germany	SCT	27	10700	CSA	+	dead (PTLD)

iEBVL: increased EBV load, CSA: Cyclosporin A, MMF: Mycofenolate mofetil, FK: Tacrolimus, SIR: Sirolimus, AZA: Azathioprine, MTX: Methotrexate, BELA: Belatacept, KT: kidney transplantation, SCT: stem cell transplantation, ST: Steroid, m: male, f: female, cop: copies, WB: whole blood, FU: follow up, ALL: acute lymphoblastic leukemia.

^aT-cell PTLD, not EBV-associated.